Alpharetroviral vectors: From a cancer-causing agent to a useful tool for human gene therapy

Viruses

Volumn 6, Issue 12, 2014, Pages 4811-4838

  Suerth, Julia D ^a   Labenski, Verena ^a   Schambach, Axel ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Alpharetroviral vector; Clinical translation; Gene therapy; Regulatory requirements; Retrovirology; Vector safety

Indexed keywords

ALPHARETROVIRUS VECTOR; CARCINOGEN; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

BETA THALASSEMIA; CELL IMMORTALIZATION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DNA MODIFICATION; FOCUS FORMING ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; GENOTOXICITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; LENTIVIRINAE; NONHUMAN; POLYADENYLATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; RETROVIRIDAE; REVIEW; RNA TRANSLATION; SAFETY; SUICIDE GENE THERAPY; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ALPHARETROVIRUS; ANIMAL; DEVICES; GENE VECTOR; GENETICS; NEOPLASMS; PHYSIOLOGY; PROCEDURES; VIRUS DNA CELL DNA INTERACTION;

ALPHARETROVIRUS; ANIMALS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; VIRUS INTEGRATION;

EID: 84923077751     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v6124811     Document Type: Review

References (153)

1. Ellermann, V.; Bang, O. Experimentelle Leukämie bei Hühnern. Zentralbl. Bakteriol. Parasitenkd. Infektionskr. Hyg. Abt. I. 1908, 46, 595–609.
2. Rous, P. A transmissible avian neoplasm. (sarcoma of the common fowl.). J. Exp. Med. 1910, 12, 696–705.
3. Rous, P. A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 1911, 13, 397–411.
4. Diamond, L.; Wolman, S.R. Charlotte friend, ph.D. 1921–1987. A scientist’s life. Ann. N. Y. Acad. Sci. 1989, 567, 1–13.
5. Temin, H.M.; Rubin, H. Characteristics of an assay for Rous sarcoma virus and Rous sarcoma cells in tissue culture. Virology 1958, 6, 669–688.
6. Bather, R. The nucleic acid of partially purified Rous No. I sarcoma virus. Br. J. Cancer 1957, 11, 611–619.
7. Rubin, H.; Temin, H.M. A radiological study of cell-virus interaction in the Rous sarcoma. Virology 1959, 7, 75–91.
8. Temin, H.M. The Participation of DNA in Rous Sarcoma Virus Production. Virology 1964, 23, 486–494.
9. Svoboda, J.; Chyle, P.; Simkovic, D.; Hilgert, I. Demonstration of the absence of infectious Rous virus in rat tumour XC, whose structurally intact cells produce Rous sarcoma when transferred to chicks. Folia Biol. 1963, 9, 77–81.
10. Baltimore, D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 1970, 226, 1209–1211.
11. Temin, H.M.; Mizutani, S. RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 1970, 226, 1211–1213.
12. Stehelin, D.; Varmus, H.E.; Bishop, J.M.; Vogt, P.K. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976, 260, 170–173.
13. Hayward, W.S.; Neel, B.G.; Astrin, S.M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 1981, 290, 475–480.
14. Neel, B.G.; Hayward, W.S.; Robinson, H.L.; Fang, J.; Astrin, S.M. Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: Oncogenesis by promoter insertion. Cell 1981, 23, 323–334.
15. Mann, R.; Mulligan, R.C.; Baltimore, D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983, 33, 153–159.
16. Williams, D.A.; Lemischka, I.R.; Nathan, D.G.; Mulligan, R.C. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 1984, 310, 476–480.
17. Dick, J.E.; Magli, M.C.; Huszar, D.; Phillips, R.A.; Bernstein, A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 1985, 42, 71–79.
18. Kohn, D.B. Update on gene therapy for immunodeficiencies. Clin. Immunol. 2010, 135, 247–254.
19. Ott, M.G.; Schmidt, M.; Schwarzwaelder, K.; Stein, S.; Siler, U.; Koehl, U.; Glimm, H.; Kuhlcke, K.; Schilz, A.; Kunkel, H., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 2006, 12, 401–409.
20. Stein, S.; Ott, M.G.; Schultze-Strasser, S.; Jauch, A.; Burwinkel, B.; Kinner, A.; Schmidt, M.; Kramer, A.; Schwable, J.; Glimm, H., et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 2010, 16, 198–204.
21. Hacein-Bey-Abina, S.; Von Kalle, C.; Schmidt, M.; McCormack, M.P.; Wulffraat, N.; Leboulch, P.; Lim, A.; Osborne, C.S.; Pawliuk, R.; Morillon, E., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003, 302, 415–419.
22. Hacein-Bey-Abina, S.; Garrigue, A.; Wang, G.P.; Soulier, J.; Lim, A.; Morillon, E.; Clappier, E.; Caccavelli, L.; Delabesse, E.; Beldjord, K., et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 2008, 118, 3132–3142.
23. Howe, S.J.; Mansour, M.R.; Schwarzwaelder, K.; Bartholomae, C.; Hubank, M.; Kempski, H.; Brugman, M.H.; Pike-Overzet, K.; Chatters, S.J.; de Ridder, D., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin Invest. 2008, 118, 3143–3150.
24. Braun, C.J.; Boztug, K.; Paruzynski, A.; Witzel, M.; Schwarzer, A.; Rothe, M.; Modlich, U.; Beier, R.; Gohring, G.; Steinemann, D., et al. Gene therapy for Wiskott-Aldrich syndrome—Long-term efficacy and genotoxicity. Sci. Transl. Med. 2014, 6, 227-233.
25. Lazo, P.A.; Lee, J.S.; Tsichlis, P.N. Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in rat T-cell lymphomas. Proc. Natl. Acad. Sci. USA 1990, 87, 170–173.
26. Bartholomew, C.; Ihle, J.N. Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter. Mol. Cell Biol. 1991, 11, 1820–1828.
27. Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Bartholomae, C.C.; Ranzani, M.; Benedicenti, F.; Sergi, L.S.; Ambrosi, A.; Ponzoni, M., et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 2009, 119, 964–975.
28. Heckl, D.; Schwarzer, A.; Haemmerle, R.; Steinemann, D.; Rudolph, C.; Skawran, B.; Knoess, S.; Krause, J.; Li, Z.; Schlegelberger, B., et al. Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol. Ther. 2012, 20, 1187–1195.
29. Cavazzana-Calvo, M.; Payen, E.; Negre, O.; Wang, G.; Hehir, K.; Fusil, F.; Down, J.; Denaro, M.; Brady, T.; Westerman, K., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010, 467, 318–322.
30. Sokol, M.; Wabl, M.; Ruiz, I.R.; Pedersen, F.S. Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors. Retrovirology 2014, 11, 36.
31. Mooslehner, K.; Karls, U.; Harbers, K. Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions. J. Virol. 1990, 64, 3056–3058.
32. Scherdin, U.; Rhodes, K.; Breindl, M. Transcriptionally active genome regions are preferred targets for retrovirus integration. J. Virol. 1990, 64, 907–912.
33. Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.; Ecker, J.R.; Bushman, F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002, 110, 521–529.
34. Wu, X.; Li, Y.; Crise, B.; Burgess, S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003, 300, 1749–1751.
35. Hematti, P.; Hong, B.K.; Ferguson, C.; Adler, R.; Hanawa, H.; Sellers, S.; Holt, I.E.; Eckfeldt, C.E.; Sharma, Y.; Schmidt, M., et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004, 2, e423.
36. Barr, S.D.; Leipzig, J.; Shinn, P.; Ecker, J.R.; Bushman, F.D. Integration targeting by avian sarcoma-leukosis virus and human immunodeficiency virus in the chicken genome. J. Virol. 2005, 79, 12035–12044.
37. Wagner, W.; Laufs, S.; Blake, J.; Schwager, C.; Wu, X.; Zeller, J.W.; Ho, A.D.; Fruehauf, S. Retroviral integration sites correlate with expressed genes in hematopoietic stem cells. Stem Cells 2005, 23, 1050–1058.
38. Beard, B.C.; Dickerson, D.; Beebe, K.; Gooch, C.; Fletcher, J.; Okbinoglu, T.; Miller, D.G.; Jacobs, M.A.; Kaul, R.; Kiem, H.P., et al. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol. Ther. 2007, 15, 1356–1365.
39. Beard, B.C.; Keyser, K.A.; Trobridge, G.D.; Peterson, L.J.; Miller, D.G.; Jacobs, M.; Kaul, R.; Kiem, H.P. Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. Hum. Gene Ther. 2007, 18, 423–434.
40. Cattoglio, C.; Facchini, G.; Sartori, D.; Antonelli, A.; Miccio, A.; Cassani, B.; Schmidt, M.; von Kalle, C.; Howe, S.; Thrasher, A.J., et al. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 2007, 110, 1770–1778.
41. Brady, T.; Agosto, L.M.; Malani, N.; Berry, C.C.; O’Doherty, U.; Bushman, F. HIV integration site distributions in resting and activated CD4+ T cells infected in culture. Aids 2009, 23, 1461–1471.
42. Shun, M.C.; Raghavendra, N.K.; Vandegraaff, N.; Daigle, J.E.; Hughes, S.; Kellam, P.; Cherepanov, P.; Engelman, A. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev. 2007, 21, 1767–1778.
43. Ciuffi, A.; Llano, M.; Poeschla, E.; Hoffmann, C.; Leipzig, J.; Shinn, P.; Ecker, J.R.; Bushman, F. A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med. 2005, 11, 1287–1289.
44. Marshall, H.M.; Ronen, K.; Berry, C.; Llano, M.; Sutherland, H.; Saenz, D.; Bickmore, W.; Poeschla, E.; Bushman, F.D. Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. PLoS One 2007, 2, e1340.
45. Cherepanov, P.; Maertens, G.; Proost, P.; Devreese, B.; Van Beeumen, J.; Engelborghs, Y.; de Clercq, E.; Debyser, Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem 2003, 278, 372–381.
46. Llano, M.; Vanegas, M.; Fregoso, O.; Saenz, D.; Chung, S.; Peretz, M.; Poeschla, E.M. LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J. Virol. 2004, 78, 9524–9537.
47. Sharma, A.; Larue, R.C.; Plumb, M.R.; Malani, N.; Male, F.; Slaughter, A.; Kessl, J.J.; Shkriabai, N.; Coward, E.; Aiyer, S.S., et al. BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc. Natl. Acad. Sci. USA 2013, 110, 12036–12041.
48. Gupta, S.S.; Maetzig, T.; Maertens, G.N.; Sharif, A.; Rothe, M.; Weidner-Glunde, M.; Galla, M.; Schambach, A.; Cherepanov, P.; Schulz, T.F. Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J. Virol. 2013, 87, 12721–12736.
49. De Rijck, J.; de Kogel, C.; Demeulemeester, J.; Vets, S.; El Ashkar, S.; Malani, N.; Bushman, F.D.; Landuyt, B.; Husson, S.J.; Busschots, K., et al. The bet family of proteins targets moloney murine leukemia virus integration near transcription start sites. Cell. Rep. 2013, 5, 886–894.
50. Gijsbers, R.; Ronen, K.; Vets, S.; Malani, N.; de Rijck, J.; McNeely, M.; Bushman, F.D.; Debyser, Z. LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. Ther. 2010, 18, 552–560.
51. Vets, S.; De Rijck, J.; Brendel, C.; Grez, M.; Bushman, F.; Debyser, Z.; Gijsbers, R. Transient Expression of an LEDGF/p75 Chimera Retargets Lentivector Integration and Functionally Rescues in a Model for X-CGD. Mol. Ther. Nucleic Acids 2013, 2, e77.
52. Hare, S.; Shun, M.C.; Gupta, S.S.; Valkov, E.; Engelman, A.; Cherepanov, P. A novel co-crystal structure affords the design of gain-of-function lentiviral integrase mutants in the presence of modified PSIP1/LEDGF/p75. PLoS Pathog. 2009, 5, e1000259.
53. Ciuffi, A.; Diamond, T.L.; Hwang, Y.; Marshall, H.M.; Bushman, F.D. Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factor. Hum. Gene Ther. 2006, 17, 960–967.
54. Ferris, A.L.; Wu, X.; Hughes, C.M.; Stewart, C.; Smith, S.J.; Milne, T.A.; Wang, G.G.; Shun, M.C.; Allis, C.D.; Engelman, A., et al. Lens epithelium-derived growth factor fusion proteins redirect HIV-1 DNA integration. Proc. Natl. Acad. Sci. USA 2010, 107, 3135–3140.
55. Aiyer, S.; Swapna, G.V.; Malani, N.; Aramini, J.M.; Schneider, W.M.; Plumb, M.R.; Ghanem, M.; Larue, R.C.; Sharma, A.; Studamire, B., et al. Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction. Nucleic Acids Res. 2014, 42, 5917–5928.
56. El Ashkar, S.; de Rijck, J.; Demeulemeester, J.; Vets, S.; Madlala, P.; Cermakova, K.; Debyser, Z.; Gijsbers, R. BET-independent MLV-based vectors target away from promoters and regulatory elements. Mol. Ther. Nucleic Acids 2014, 3, e179.
57. Mitchell, R.S.; Beitzel, B.F.; Schroder, A.R.; Shinn, P.; Chen, H.; Berry, C.C.; Ecker, J.R.; Bushman, F.D. Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences. PLoS Biol. 2004, 2, E234.
58. Narezkina, A.; Taganov, K.D.; Litwin, S.; Stoyanova, R.; Hayashi, J.; Seeger, C.; Skalka, A.M.; Katz, R.A. Genome-wide analyses of avian sarcoma virus integration sites. J. Virol. 2004, 78, 11656–11663.
59. Hu, J.; Renaud, G.; Gomes, T.J.; Ferris, A.; Hendrie, P.C.; Donahue, R.E.; Hughes, S.H.; Wolfsberg, T.G.; Russell, D.W.; Dunbar, C.E. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors. Mol. Ther. 2008, 16, 1617–1623.
60. Suerth, J.D.; Maetzig, T.; Brugman, M.H.; Heinz, N.; Appelt, J.U.; Kaufmann, K.B.; Schmidt, M.; Grez, M.; Modlich, U.; Baum, C., et al. Alpharetroviral self-inactivating vectors: Long-term transgene expression in murine hematopoietic cells and low genotoxicity. Mol. Ther. 2012, 20, 1022–1032.
61. Moiani, A.; Suerth, J.D.; Gandolfi, F.; Rizzi, E.; Severgnini, M.; de Bellis, G.; Schambach, A.; Mavilio, F. Genome-wide analysis of alpharetroviral integration in human hematopoietic stem/progenitor cells. Genes 2014, 5, 415–429.
62. Donahue, R.E.; Kessler, S.W.; Bodine, D.; McDonagh, K.; Dunbar, C.; Goodman, S.; Agricola, B.; Byrne, E.; Raffeld, M.; Moen, R. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 1992, 176, 1125–1135.
63. Cesana, D.; Ranzani, M.; Volpin, M.; Bartholomae, C.; Duros, C.; Artus, A.; Merella, S.; Benedicenti, F.; Sergi Sergi, L.; Sanvito, F., et al. Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo. Mol. Ther. 2014, 22, 774–785.
64. Watanabe, S.; Temin, H.M. Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol. Cell Biol. 1983, 3, 2241–2249.
65. Miller, A.D.; Rosman, G.J. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989, 7, 980–990.
66. Soneoka, Y.; Cannon, P.M.; Ramsdale, E.E.; Griffiths, J.C.; Romano, G.; Kingsman, S.M.; Kingsman, A.J. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995, 23, 628–633.
67. Yu, S.F.; von Ruden, T.; Kantoff, P.W.; Garber, C.; Seiberg, M.; Ruther, U.; Anderson, W.F.; Wagner, E.F.; Gilboa, E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 1986, 83, 3194–3198.
68. Zufferey, R.; Dull, T.; Mandel, R.J.; Bukovsky, A.; Quiroz, D.; Naldini, L.; Trono, D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 1998, 72, 9873–9880.
69. Modlich, U.; Bohne, J.; Schmidt, M.; von Kalle, C.; Knoss, S.; Schambach, A.; Baum, C. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 2006, 108, 2545–2553.
70. Zychlinski, D.; Schambach, A.; Modlich, U.; Maetzig, T.; Meyer, J.; Grassman, E.; Mishra, A.; Baum, C. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 2008, 16, 718–725.
71. Baum, C.; Dullmann, J.; Li, Z.; Fehse, B.; Meyer, J.; Williams, D.A.; von Kalle, C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003, 101, 2099–2114.
72. Lamers, C.H.; Willemsen, R.; van Elzakker, P.; van Steenbergen-Langeveld, S.; Broertjes, M.; Oosterwijk-Wakka, J.; Oosterwijk, E.; Sleijfer, S.; Debets, R.; Gratama, J.W. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 2011, 117, 72–82.
73. Kondo, E.; Akatsuka, Y.; Nawa, A.; Kuzushima, K.; Tsujimura, K.; Tanimoto, M.; Kodera, Y.; Morishima, Y.; Kuzuya, K.; Takahashi, T. Retroviral vector backbone immunogenicity: Identification of cytotoxic t-cell epitopes in retroviral vector-packaging sequences. Gene Ther. 2005, 12, 252–258.
74. Federspiel, M.J.; Hughes, S.H. Retroviral gene delivery. Methods Cell Biol. 1997, 52, 179–214.
75. Hughes, S.H. The RCAS vector system. Folia Biol. 2004, 50, 107–119.
76. Svoboda, J. Molecular biology of cell nonpermissiveness to retroviruses. Has the time come? Gene 1998, 206, 153–163.
77. Hu, J.; Ferris, A.; Larochelle, A.; Krouse, A.E.; Metzger, M.E.; Donahue, R.E.; Hughes, S.H.; Dunbar, C.E. Transduction of rhesus macaque hematopoietic stem and progenitor cells with avian sarcoma and leukosis virus vectors. Hum. Gene Ther. 2007, 18, 691–700.
78. Dong, J.; Roth, M.G.; Hunter, E. A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J. Virol. 1992, 66, 7374–7382.
79. Barsov, E.V.; Hughes, S.H. Gene transfer into mammalian cells by a Rous sarcoma virus-based retroviral vector with the host range of the amphotropic murine leukemia virus. J. Virol. 1996, 70, 3922–3929.
80. Dull, T.; Zufferey, R.; Kelly, M.; Mandel, R.J.; Nguyen, M.; Trono, D.; Naldini, L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72, 8463–8471.
81. Kraunus, J.; Schaumann, D.H.S.; Meyer, J.; Modlich, U.; Fehse, B.; Brandenburg, G.; von Laer, D.; Klump, H.; Schambach, A.; Bohne, J., et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Therapy 2004, 11, 1568–1578.
82. Schambach, A.; Mueller, D.; Galla, M.; Verstegen, M.M.; Wagemaker, G.; Loew, R.; Baum, C.; Bohne, J. Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors. Gene Ther. 2006, 13, 1524–1533.
83. Suerth, J.D.; Maetzig, T.; Galla, M.; Baum, C.; Schambach, A. Self-inactivating alpharetroviral vectors with a split-packaging design. J. Virol. 2010, 84, 6626–6635.
84. Ruddell, A. Transcription regulatory elements of the avian retroviral long terminal repeat. Virology 1995, 206, 1–7.
85. Modlich, U.; Navarro, S.; Zychlinski, D.; Maetzig, T.; Knoess, S.; Brugman, M.H.; Schambach, A.; Charrier, S.; Galy, A.; Thrasher, A.J., et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther. 2009, 17, 1919–1928.
86. Xu, W.; Russ, J.L.; Eiden, M.V. Evaluation of residual promoter activity in gamma-retroviral self-inactivating (SIN) vectors. Mol. Ther. 2012, 20, 84–90.
87. Kaufmann, K.B.; Brendel, C.; Suerth, J.D.; Mueller-Kuller, U.; Chen-Wichmann, L.; Schwable, J.; Pahujani, S.; Kunkel, H.; Schambach, A.; Baum, C., et al. Alpharetroviral vector-mediated gene therapy for X-CGD: Functional correction and lack of aberrant splicing. Mol. Ther. 2012, 21, 648–661.
88. Yoder, J.A.; Walsh, C.P.; Bestor, T.H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 1997, 13, 335–340.
89. Barklis, E.; Mulligan, R.C.; Jaenisch, R. Chromosomal position or virus mutation permits retrovirus expression in embryonal carcinoma cells. Cell 1986, 47, 391–399.
90. Flanagan, J.R.; Krieg, A.M.; Max, E.E.; Khan, A.S. Negative control region at the 5' end of murine leukemia virus long terminal repeats. Mol. Cell Biol. 1989, 9, 739–746.
91. Ellis, J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum. Gene Ther. 2005, 16, 1241–1246.
92. Greger, J.G.; Katz, R.A.; Ishov, A.M.; Maul, G.G.; Skalka, A.M. The cellular protein daxx interacts with avian sarcoma virus integrase and viral DNA to repress viral transcription. J. Virol. 2005, 79, 4610–4618.
93. Poleshko, A.; Palagin, I.; Zhang, R.; Boimel, P.; Castagna, C.; Adams, P.D.; Skalka, A.M.; Katz, R.A. Identification of cellular proteins that maintain retroviral epigenetic silencing: Evidence for an antiviral response. J. Virol. 2008, 82, 2313–2323.
94. Katz, R.A.; Jack-Scott, E.; Narezkina, A.; Palagin, I.; Boimel, P.; Kulkosky, J.; Nicolas, E.; Greger, J.G.; Skalka, A.M. High-frequency epigenetic repression and silencing of retroviruses can be antagonized by histone deacetylase inhibitors and transcriptional activators, but uniform reactivation in cell clones is restricted by additional mechanisms. J. Virol. 2007, 81, 2592–2604.
95. Shalginskikh, N.; Poleshko, A.; Skalka, A.M.; Katz, R.A. Retroviral DNA methylation and epigenetic repression are mediated by the antiviral host protein Daxx. J. Virol. 2013, 87, 2137–2150.
96. Hejnar, J.; Plachy, J.; Geryk, J.; Machon, O.; Trejbalova, K.; Guntaka, R.V.; Svoboda, J. Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: Different sensitivity in permissive chicken cells versus mammalian cells. Virology 1999, 255, 171–181.
97. Hejnar, J.; Svoboda, J.; Geryk, J.; Fincham, V.J.; Hak, R. High rate of morphological reversion in tumor cell line H-19 associated with permanent transcriptional suppression of the LTR, v-src, LTR provirus. Cell Growth Differ. 1994, 5, 277–285.
98. Searle, S.; Gillespie, D.A.; Chiswell, D.J.; Wyke, J.A. Analysis of the variations in proviral cytosine methylation that accompany transformation and morphological reversion in a line of Rous sarcoma virus-infected Rat-1 cells. Nucleic Acids Res. 1984, 12, 5193–5210.
99. Jahner, D.; Stuhlmann, H.; Stewart, C.L.; Harbers, K.; Lohler, J.; Simon, I.; Jaenisch, R. De novo methylation and expression of retroviral genomes during mouse embryogenesis. Nature 1982, 298, 623–628.
100. Klug, C.A.; Cheshier, S.; Weissman, I.L. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 2000, 96, 894–901.
101. Hoeben, R.C.; Migchielsen, A.A.; van der Jagt, R.C.; van Ormondt, H.; van der Eb, A.J. Inactivation of the Moloney murine leukemia virus long terminal repeat in murine fibroblast cell lines is associated with methylation and dependent on its chromosomal position. J. Virol. 1991, 65, 904–912.
102. Plachy, J.; Kotab, J.; Divina, P.; Reinisova, M.; Senigl, F.; Hejnar, J. Proviruses selected for high and stable expression of transduced genes accumulate in broadly transcribed genome areas. J. Virol. 2010, 84, 4204–4211.
103. Senigl, F.; Auxt, M.; Hejnar, J. Transcriptional provirus silencing as a crosstalk of de novo DNA methylation and epigenomic features at the integration site. Nucleic Acids Res. 2012, 40, 5298–5312.
104. Antoniou, M.N.; Skipper, K.A.; Anakok, O. Optimizing retroviral gene expression for effective therapies. Hum. Gene Ther. 2013, 24, 363–374.
105. Benabdellah, K.; Gutierrez-Guerrero, A.; Cobo, M.; Munoz, P.; Martin, F. A chimeric HS4-SAR insulator (IS2) that prevents silencing and enhances expression of lentiviral vectors in pluripotent stem cells. PLoS One 2014, 9, e84268.
106. Senigl, F.; Plachy, J.; Hejnar, J. The core element of a CpG island protects avian sarcoma and leukosis virus-derived vectors from transcriptional silencing. J. Virol. 2008, 82, 7818–7827.
107. Hejnar, J.; Hajkova, P.; Plachy, J.; Elleder, D.; Stepanets, V.; Svoboda, J. CpG island protects Rous sarcoma virus-derived vectors integrated into nonpermissive cells from DNA methylation and transcriptional suppression. Proc. Natl. Acad. Sci. USA 2001, 98, 565–569.
108. Merten, O.W. State-of-the-art of the production of retroviral vectors. J. Gene Med. 2004, 6, S105–S124.
109. Coroadinha, A.S.; Gama-Norton, L.; Amaral, A.I.; Hauser, H.; Alves, P.M.; Cruz, P.E. Production of retroviral vectors: Review. Curr. Gene Ther. 2010, 10, 456–473.
110. Chong, H.; Starkey, W.; Vile, R.G. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J. Virol. 1998, 72, 2663–2670.
111. U.S. Food and Drug Administration. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. Available online: http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ucm072987.htm (accessed on 1 December 2014).
112. Ni, Y.; Sun, S.; Oparaocha, I.; Humeau, L.; Davis, B.; Cohen, R.; Binder, G.; Chang, Y.N.; Slepushkin, V.; Dropulic, B. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med. 2005, 7, 818–834.
113. Otto, E.; Jones-Trower, A.; Vanin, E.F.; Stambaugh, K.; Mueller, S.N.; Anderson, W.F.; McGarrity, G.J. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum. Gene Ther. 1994, 5, 567–575.
114. Von Werder, A.; Seidler, B.; Schmid, R.M.; Schneider, G.; Saur, D. Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system. Nat. Protoc. 2012, 7, 1167–1183.
115. Bear, A.S.; Morgan, R.A.; Cornetta, K.; June, C.H.; Binder-Scholl, G.; Dudley, M.E.; Feldman, S.A.; Rosenberg, S.A.; Shurtleff, S.A.; Rooney, C.M.; et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: Is it time to revise the testing requirements? Mol. Ther. 2012, 20, 246–249.
116. Ikeda, Y.; Takeuchi, Y.; Martin, F.; Cosset, F.L.; Mitrophanous, K.; Collins, M. Continuous high-titer HIV-1 vector production. Nat. Biotechnol. 2003, 21, 569–572.
117. Cosset, F.L.; Legras, C.; Chebloune, Y.; Savatier, P.; Thoraval, P.; Thomas, J.L.; Samarut, J.; Nigon, V.M.; Verdier, G. A new avian leukosis virus-based packaging cell line that uses two separate transcomplementing helper genomes. J. Virol. 1990, 64, 1070–1078.
118. Schaefer-Klein, J.; Givol, I.; Barsov, E.V.; Whitcomb, J.M.; VanBrocklin, M.; Foster, D.N.; Federspiel, M.J.; Hughes, S.H. The EV-O-derived cell line DF-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors. Virology 1998, 248, 305–311.
119. Himly, M.; Foster, D.N.; Bottoli, I.; Iacovoni, J.S.; Vogt, P.K. The DF-1 chicken fibroblast cell line: Transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology 1998, 248, 295–304.
120. Loftus, S.K.; Larson, D.M.; Watkins-Chow, D.; Church, D.M.; Pavan, W.J. Generation of RCAS vectors useful for functional genomic analyses. DNA Res. 2001, 8, 221–226.
121. Suerth, J.D.; Schambach, A.; Baum, C. Genetic modification of lymphocytes by retrovirus-based vectors. Curr. Opin. Immunol. 2012, 24, 598–608.
122. Hotta, A.; Saito, Y.; Kyogoku, K.; Kawabe, Y.; Nishijima, K.; Kamihira, M.; Iijima, S. Characterization of transient expression system for retroviral vector production. J. Biosci. Bioeng. 2006, 101, 361–368.
123. Sandrin, V.; Boson, B.; Salmon, P.; Gay, W.; Negre, D.; Le Grand, R.; Trono, D.; Cosset, F.L. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100, 823–832.
124. Ghani, K.; Cottin, S.; Kamen, A.; Caruso, M. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media. Gene Ther. 2007, 14, 1705–1711.
125. Le Doux, J.M.; Morgan, J.R.; Snow, R.G.; Yarmush, M.L. Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J. Virol. 1996, 70, 6468–6473.
126. Suomalainen, M.; Garoff, H. Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus. J. Virol. 1994, 68, 4879–4889.
127. Cosset, F.L.; Takeuchi, Y.; Battini, J.L.; Weiss, R.A.; Collins, M.K. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 1995, 69, 7430–7436.
128. Wicke, D.C.; Meyer, J.; Buesche, G.; Heckl, D.; Kreipe, H.; Li, Z.; Welte, K.H.; Ballmaier, M.; Baum, C.; Modlich, U. Gene therapy of MPL deficiency: Challenging balance between leukemia and pancytopenia. Mol. Ther. 2010, 18, 343–352.
129. Voelkel, C.; Galla, M.; Dannhauser, P.N.; Maetzig, T.; Sodeik, B.; Schambach, A.; Baum, C. Pseudotype-independent nonspecific uptake of gammaretroviral and lentiviral particles in human cells. Hum. Gene Ther. 2012, 23, 274–286.
130. Hacein-Bey-Abina, S.; Hauer, J.; Lim, A.; Picard, C.; Wang, G.P.; Berry, C.C.; Martinache, C.; Rieux-Laucat, F.; Latour, S.; Belohradsky, B.H.; et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2010, 363, 355–364.
131. Gaspar, H.B.; Cooray, S.; Gilmour, K.C.; Parsley, K.L.; Adams, S.; Howe, S.J.; Al Ghonaium, A.; Bayford, J.; Brown, L.; Davies, E.G.; et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med. 2011, 3, 97-79.
132. Aiuti, A.; Cattaneo, F.; Galimberti, S.; Benninghoff, U.; Cassani, B.; Callegaro, L.; Scaramuzza, S.; Andolfi, G.; Mirolo, M.; Brigida, I., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009, 360, 447–458.
133. Aiuti, A.; Biasco, L.; Scaramuzza, S.; Ferrua, F.; Cicalese, M.P.; Baricordi, C.; Dionisio, F.; Calabria, A.; Giannelli, S.; Castiello, M.C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013, 341, 1233151.
134. Cartier, N.; Hacein-Bey-Abina, S.; Bartholomae, C.C.; Veres, G.; Schmidt, M.; Kutschera, I.; Vidaud, M.; Abel, U.; Dal-Cortivo, L.; Caccavelli, L., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326, 818–823.
135. Biffi, A.; Montini, E.; Lorioli, L.; Cesani, M.; Fumagalli, F.; Plati, T.; Baldoli, C.; Martino, S.; Calabria, A.; Canale, S., et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013, 341, 1233158.
136. Rosenberg, S.A.; Aebersold, P.; Cornetta, K.; Kasid, A.; Morgan, R.A.; Moen, R.; Karson, E.M.; Lotze, M.T.; Yang, J.C.; Topalian, S.L., et al. Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J. Med. 1990, 323, 570–578.
137. Morgan, R.A.; Dudley, M.E.; Wunderlich, J.R.; Hughes, M.S.; Yang, J.C.; Sherry, R.M.; Royal, R.E.; Topalian, S.L.; Kammula, U.S.; Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314, 126–129.
138. Parkhurst, M.R.; Yang, J.C.; Langan, R.C.; Dudley, M.E.; Nathan, D.A.; Feldman, S.A.; Davis, J.L.; Morgan, R.A.; Merino, M.J.; Sherry, R.M., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 2011, 19, 620–626.
139. Robbins, P.F.; Morgan, R.A.; Feldman, S.A.; Yang, J.C.; Sherry, R.M.; Dudley, M.E.; Wunderlich, J.R.; Nahvi, A.V.; Helman, L.J.; Mackall, C.L., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29, 917–924.
140. Hart, D.P.; Xue, S.A.; Thomas, S.; Cesco-Gaspere, M.; Tranter, A.; Willcox, B.; Lee, S.P.; Steven, N.; Morris, E.C.; Stauss, H.J. Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Ther. 2008, 15, 625–631.
141. Dotti, G.; Gottschalk, S.; Savoldo, B.; Brenner, M.K. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 2014, 257, 107–126.
142. Sadelain, M.; Brentjens, R.; Riviere, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013, 3, 388–398.
143. Kalos, M.; Levine, B.L.; Porter, D.L.; Katz, S.; Grupp, S.A.; Bagg, A.; June, C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3, 95-73.
144. Kochenderfer, J.N.; Wilson, W.H.; Janik, J.E.; Dudley, M.E.; Stetler-Stevenson, M.; Feldman, S.A.; Maric, I.; Raffeld, M.; Nathan, D.A.; Lanier, B.J., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116, 4099–4102.
145. Brentjens, R.J.; Riviere, I.; Park, J.H.; Davila, M.L.; Wang, X.; Stefanski, J.; Taylor, C.; Yeh, R.; Bartido, S.; Borquez-Ojeda, O., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118, 4817–4828.
146. Louis, C.U.; Savoldo, B.; Dotti, G.; Pule, M.; Yvon, E.; Myers, G.D.; Rossig, C.; Russell, H.V.; Diouf, O.; Liu, E., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118, 6050–6056.
147. Bonini, C.; Ferrari, G.; Verzeletti, S.; Servida, P.; Zappone, E.; Ruggieri, L.; Ponzoni, M.; Rossini, S.; Mavilio, F.; Traversari, C., et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276, 1719–1724.
148. Ciceri, F.; Bonini, C.; Stanghellini, M.T.; Bondanza, A.; Traversari, C.; Salomoni, M.; Turchetto, L.; Colombi, S.; Bernardi, M.; Peccatori, J., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009, 10, 489–500.
149. Di Stasi, A.; Tey, S.K.; Dotti, G.; Fujita, Y.; Kennedy-Nasser, A.; Martinez, C.; Straathof, K.; Liu, E.; Durett, A.G.; Grilley, B., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365, 1673–1683.
150. Scholler, J.; Brady, T.L.; Binder-Scholl, G.; Hwang, W.T.; Plesa, G.; Hege, K.M.; Vogel, A.N.; Kalos, M.; Riley, J.L.; Deeks, S.G., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci. Transl. Med. 2012, 4, 132-153.
151. Newrzela, S.; Al-Ghaili, N.; Heinrich, T.; Petkova, M.; Hartmann, S.; Rengstl, B.; Kumar, A.; Jack, H.M.; Gerdes, S.; Roeder, I., et al. T-cell receptor diversity prevents T-cell lymphoma development. Leukemia 2012, 26, 2499–2507.
152. Newrzela, S.; Cornils, K.; Li, Z.; Baum, C.; Brugman, M.H.; Hartmann, M.; Meyer, J.; Hartmann, S.; Hansmann, M.L.; Fehse, B., et al. Resistance of mature T cells to oncogene transformation. Blood 2008, 112, 2278–2286.
153. Heinrich, T.; Rengstl, B.; Muik, A.; Petkova, M.; Schmid, F.; Wistinghausen, R.; Warner, K.; Crispatzu, G.; Hansmann, M.L.; Herling, M., et al. Mature T-cell lymphomagenesis induced by retroviral insertional activation of janus kinase 1. Mol. Ther. 2013, 21, 1160–1168.